Background
Methods
2.1 Patients
2.2 Controls
2.3 Clinic and Laboratory Evaluation
2.4 Study Protocol
2.5 Histological Assessment
2.6 Statistical Analysis
Results
3.1 Characteristics of the patient and control population
A | ||
---|---|---|
Baseline characteristics for men. Data are reported as median and range | ||
Chronic viral hepatitis patients (n = 36) | Control Subjects (n = 17) | |
Age (years)
| 45.5 (19,73) | 62.5 (21,79) |
Height (cm)
| 173 (160,190) | 173 (167,186) |
Weight (kg)
| 81.5 (58,118) | 75 (62,100) |
BMI (kg/m
2
)
| 26.3 (20.3,36.2) | 25.1 (21.5, 29.5) |
FMI
| 9.99 (5.5, 17.4) | 9.09 (6.39, 12.4) |
Glucose (mg/dl)
| 96.5 (70,147)* | 88 (60,183) |
Insulin (μU/mL)
| 7.34 (0.73, 125.8) | 9.18 (3.05,17.28) |
HOMA-IR
| 2 (0.12–7.36) | 2 (0.88–4.89) |
AST (IU/l)
| 59 (19,274)* | 26 (21,35) |
ALT (IU/l)
| 105 (24,366)* | 25 (20,36) |
Leptin (pg/ml)
| 5134 (695,30430) | 5054 (588,15325) |
B
| ||
Baseline characteristics for women. Data are reported as median and range | ||
Chronic viral hepatitis patients (n = 14)
|
Control Subjects (n = 15)
| |
Age (years)
| 38 (16,70) | 51 (20,74) |
Height (cm)
| 165 (156,169) | 160 (153,168) |
Weight (kg)
| 77 (51,112) | 74 (60,94) |
BMI (kg/m
2
)
| 29.7 (18,39.3) | 29.5 (23.1,38.8) |
FMI
| 12.6 (3.81,19.7) | 12.4 (7.59,17.39) |
Glucose (mg/dl)
| 80.5 (70,175) | 81 (60,156) |
Insulin (μU/mL)
| 5.65 (0.73,16.47) | 8.43 (5.67,67.76) |
HOMA-IR
| 1.02 (0.12, 6.25) | 1.53 (0.95–13.5) |
AST (IU/l)
| 55 (38,129)* | 27 (20,35) |
ALT (IU/l)
| 66 (54,269)* | 27 (21,32) |
Leptin (pg/ml)
| 11372(1714,43605) | 18990(4876,48928) |
Hepatitis B patients | Hepatitis C patients | |||
---|---|---|---|---|
Liver biopsy features | Baseline liver biopsy | Liver Biopsy after treatment | Baseline liver biopsy | Liver Biopsy after treatment |
HAI*1
| 8(3,13)*1
| 4 (0,12)*1
| 7 (2,14)*1
| 4 (0,9)*1
|
0–8 N(%) | 11(44) | 18 (78.26) | 16 (64) | 10 (77) |
9–12 N(%) | 13 (52) | 5 (21.74) | 8 (32) | 3 (23) |
> 12 N(%) | 1 (4) | 0 | 1 (4) | 0 |
Fibrosis
| 4 (1,6) | 2 (0,6) | 3 (1,6) | 2 (0,6) |
Cirrhosis N(%)*2
| 9 (36) | 5 (21.74) | 5 (20) | 3 (23) |
Steatosis*3
| 0(0,1) | 4 (0,12) | 0 (0,3) | 0 (0,1) |
No steatosis N(%) | 16(64) | 19 (82.61) | 13 (54.17) | 12 (92.3) |
Mild N(%) | 9 (36) | 4 (17.39) | 10 (41.67) | 1(7.69) |
Moderate N (%) | 0 | 0 | 0 | 0 |
Severe N (%) | 0 | 0 | 1 (4.17) | 0 |
3.2 Relationship between serum leptin and insulin levels and clinical, biochemical and histological data of patients and controls
3.3 Factors associated with virologic response to antiviral treatment
Total number of responders (n = 30) | Total number of non-responders (n = 20) | p-value | |
Leptin (pg/ml)
| 4642.5 (917, 32879)* | 10733 (695, 43605) | 0.002 |
CHB patients
|
Responders to lamivudine monotherapy (n = 19)
|
Non-responders to lamivudine monotherapy (n = 6)
|
p-value
|
Leptin (pg/ml)
| 5334 (917, 17436) | 13111.5 (8844,43605) | 0.003 |
CHC patients
|
Sustained responders (n = 11)
|
Nonsustained responders (n = 14)
|
p-value
|
Genotype 3
| 7 (63.6%) | 4/14 (28%) | 0.01 |